R-3750

About Virtici

Virtici is a private, San Francisco-based biotech founded in 2019 that functions as an innovation engine and product developer in digital health and AI/machine learning. Its business model involves identifying and validating early-stage scientific concepts, strengthening intellectual property, and advancing them into clinical evaluation through partnerships or startup affiliates, as evidenced by its advancing pipeline. The company is currently pre-revenue, with its lead program, VTC-880 for periodontitis, in Phase 2 development via an NIH SBIR grant, and it maintains a focus on several therapeutic areas including inflammation, oncology, and autoimmunity.

About Rise Therapeutics

Rise Therapeutics is a private, clinical-stage biotech developing first-in-class oral immunotherapies for autoimmune diseases and cancer. Its core innovation is a proprietary oral drug delivery platform that enables the targeted delivery of biologic therapies, a significant advancement over traditional injectable biologics. The company has built integrated capabilities from discovery through in-house GMP manufacturing, accelerating multiple programs into clinical trials. With four active clinical programs and recent funding, Rise is positioned to validate its platform and address major unmet needs in immunology.

Therapeutic Areas

Other Ulcerative Colitis Drugs